Search
Chlorpropamide
go.drugbank.com/drugs/DB00672ApprovedWithdrawnUp to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. … Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33).
Categories: Drugs Used in DiabetesSynonyms: N-(4-chlorophenylsulfonyl)-N'-propylurea, N-(p-chlorobenzenesulfonyl)-N'-propylureaInfluenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10791ApprovedInvestigationalWithdrawnInactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. … that it was previously exposed to.
Mixtures: Medical Provider Single Use EZ Flu Shot Fluzone 2016-2017Penicillamine
go.drugbank.com/drugs/DB00859ApprovedInvestigationalIt is an α-amino acid metabolite of penicillin, although it has no antibiotic properties. … The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine).
Categories: Compounds used in a research, industrial, or household settingMeprobamate
go.drugbank.com/drugs/DB00371ApprovedIllicitIt is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
Aprepitant
go.drugbank.com/drugs/DB00673ApprovedInvestigationalAprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting … Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
Antihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalAntihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … PEGylation decreases factor VIII clearance and allowing for an increased duration of drug circulation in the plasma [L1529].
Categories: Compounds used in a research, industrial, or household settingFavezelimab
go.drugbank.com/drugs/DB16729InvestigationalFavezelimab is under investigation in clinical trial NCT04626479 (Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A
Allovectin-7
go.drugbank.com/drugs/DB17439InvestigationalIt was discontinued after it failed to improve the objective response rate or overall survival versus first-line chemotherapy in malignant melanoma.[A255207]
Milnacipran
go.drugbank.com/drugs/DB04896ApprovedInvestigationalMilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment … important role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846].
Nifurtimox
go.drugbank.com/drugs/DB11820ApprovedInvestigationalOn August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials. … Chagas disease, caused by a parasite known as Trypanosoma cruzi (T.cruzi), is a vector-transmitted disease affecting animals and humans in the Americas.